UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 13, 2021
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||||||||
(Address of principal executive offices) (Zip code)
Registrant’s telephone number, including area code: 781 -848-7100
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): | |||||
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
| Securities registered pursuant to Section 12(b) of the Act: | ||||||||
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
| Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). | ||
Emerging Growth Company | ||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ | ||
Item 2.02 Results of Operations and Financial Condition.
On May 13, 2021 , Haemonetics Corporation issued a press release announcing financial results for the fourth quarter and year ended April 3, 2021. A copy of the release is furnished with this report as Exhibit 99.1.
The foregoing information, including the exhibit attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit Number | Description | |||||||
Press Release of Haemonetics Corporation dated | ||||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| HAEMONETICS CORPORATION | ||||||||||||||
| Date : May 13, 2021 | By: | /s/ Christopher A. Simon | ||||||||||||
| Name: | Christopher A. Simon | |||||||||||||
| Title: | President and Chief Executive Officer | |||||||||||||
| Exhibit 99.1 | |||||||||||
| Investor Contact | Media Contact | ||||||||||
| Olga Guyette, Director-Investor Relations | Carla Burigatto, VP-Communications | ||||||||||
| (781) 356-9763 | (781) 348-7263 | ||||||||||
| olga.guyette@haemonetics.com | carla.burigatto@haemonetics.com | ||||||||||
Haemonetics Reports Fourth Quarter and Fiscal 2021 Results;
Provides Fiscal 2022 Guidance
Boston, MA, May 13, 2021 - Haemonetics Corporation (NYSE: HAE) reported financial results for its fourth quarter and fiscal 2021, which ended April 3, 2021:
| 4th Quarter 2021 | Fiscal 2021 | ||||||||||
■Revenue, decrease | $225 million, (6%) | $870 million, (12%) | |||||||||
■Revenue decrease (organic)1 | (14%) | (13%) | |||||||||
■(Loss) per share/earnings per diluted share | ($0.22) | $1.55 | |||||||||
■Adjusted earnings per diluted share | $0.46 | $2.35 | |||||||||
■Cash flow from operating activities | $2 million | $109 million | |||||||||
■Free cash flow before restructuring & turnaround | $0 million | $99 million | |||||||||
1Excludes the impact of currency fluctuation, strategic exits of product lines, acquisitions and divestitures and the impact of the 53rd week in fiscal 2021. | |||||||||||
Chris Simon, Haemonetics’ CEO, stated: “The pandemic affected fiscal 2021, particularly our Plasma business, but cost mitigation efforts coupled with the Operational Excellence Program helped dampen the impact. We took meaningful steps to position the Company for growth, including the Persona® launch, the Cardiva Medical acquisition, various divestitures and the debt refinancing. We remain confident in the strong end-market demand for our products and expect full recovery from the pandemic by the end of this fiscal year. Our guidance reflects the variable pace of that recovery across our different business segments. We are acting with urgency to develop a comprehensive response to the anticipated loss of a major customer in mid-calendar 2022.”
GAAP RESULTS
Fourth quarter fiscal 2021 revenue was $225.0 million, down 5.6% compared with fiscal 2020, primarily driven by the continued impact of COVID-19. Business unit revenue and growth rates compared with the prior year were as follows:
1
| ($ millions) | 4th Quarter 2021 Reported | ||||||||||
| Plasma | $ 83.7 | (25.2%) | |||||||||
| Hospital | $ 62.2 | 35.8% | |||||||||
| Blood Center | $ 73.8 | (3.6%) | |||||||||
| Net business unit revenue | $219.7 | (6.2%) | |||||||||
| Service | $ 5.4 | 26.2% | |||||||||
| Total net revenue | $225.0 | (5.6%) | |||||||||
Gross margin was 36.4% in the fourth quarter of fiscal 2021, compared with 47.6% in fiscal 2020. The decrease in gross margin was primarily due to a $20.9 million asset impairment incurred in the fourth quarter of fiscal 2021, as discussed below. Operating expenses were $103.0 million in the fourth quarter of fiscal 2021, compared with $87.6 million in the prior year. The Company had an operating loss of $21.2 million and a (9.4%) operating margin in the fourth quarter of fiscal 2021, compared with operating income of $26.0 million and an operating margin of 10.9% in fiscal 2020. The income tax rates were (60%) and 20% in the fourth quarters of fiscal 2021 and fiscal 2020, respectively. Fourth quarter fiscal 2021 net loss and net loss per share were $11.0 million and $0.22, respectively, compared with net income and earnings per diluted share of $17.6 million and $0.34, respectively, in fiscal 2020.
ADJUSTED RESULTS
Organic revenue for the fourth quarter of fiscal 2021 was down 13.7% compared with the prior year, primarily driven by the continued impact of COVID-19. Business unit organic revenue growth rates compared with the prior year were as follows:
4th Quarter 2021 Organic | |||||
| Plasma | (28.3%) | ||||
| Hospital | 11.7% | ||||
| Blood Center | (9.8%) | ||||
| Net business unit revenue | (14.3%) | ||||
| Service | 19.4% | ||||
| Total net revenue | (13.7%) | ||||
Within Hospital, organic revenue growth in the Hemostasis Management product line was 19.1% in the fourth quarter of fiscal 2021 compared with the prior year.
Fourth quarter fiscal 2021 adjusted gross margin was 50.0%, down 30 basis points compared with the prior year. The primary drivers of this decline were higher inventory related charges, the impact of recent divestitures and unfavorable pricing and product mix mainly due to the impact of COVID-19, partially offset by recent acquisitions and productivity savings from the Operational Excellence Program and lower depreciation.
Adjusted operating expenses in the fourth quarter of fiscal 2021 were $81.9 million, up $9.2 million, or 12.7%, compared with the prior year. The increase in adjusted operating expenses
2
was primarily driven by an increase in variable compensation and the acquisition of Cardiva Medical, Inc. (“Cardiva Medical”), partially offset by productivity savings and cost containment actions to help offset the negative effects of COVID-19. Adjusted operating income for the fourth quarter of fiscal 2021 was $30.5 million, down $16.8 million or 35.5%, and adjusted operating margin was 13.5%, down 630 basis points when compared with fiscal 2020. The adjusted income tax rate was 12% in the fourth quarter of fiscal 2021 compared with an adjusted income tax rate of 18% in fiscal 2020.
Fourth quarter fiscal 2021 adjusted net income was $23.9 million, down $11.5 million or 32.5%, and adjusted earnings per diluted share was $0.46, down 33.3% when compared with fiscal 2020.
BALANCE SHEET AND CASH FLOW
Cash on hand at April 3, 2021 was $192.3 million, an increase of $55.0 million since March 28, 2020. Cash flow from operating activities was $108.8 million and free cash flow before restructuring and turnaround funding requirements was $99.2 million during fiscal 2021, compared with $158.2 million and $139.4 million, respectively, in fiscal 2020. During fiscal 2021, cash flow from operating activities and free cash flow before restructuring and turnaround funding requirements included a $54.3 million payment for a compensation-related liability as part of the Cardiva Medical acquisition. The total purchase price paid for Cardiva Medical was reduced by the amount of this liability.
During fiscal 2021, the Company also received $439.1 million of net cash from the issuance of convertible notes and $44.6 million of net cash from divestitures. The Company utilized $434.8 million of cash for acquisitions and reduced net borrowings under its revolving credit line and long-term debt facility by $60.0 million and $21.9 million, respectively, during fiscal 2021.
RESTRUCTURING AND TURNAROUND COSTS, DEAL AMORTIZATION, ASSET IMPAIRMENTS, TRANSACTION AND INTEGRATION COSTS
The Company incurred restructuring and turnaround costs of $4.1 million in the fourth quarter of fiscal 2021 compared with $6.3 million in fiscal 2020 and deal amortization expenses of $8.6 million in the fourth quarter of fiscal 2021 compared with $8.1 million in fiscal 2020.
In addition, during the fourth quarter of fiscal 2021, the Company incurred an asset impairment of $20.9 million in connection with the recent announcement of CSL Plasma, Ltd.’s intent not to renew its long-term supply agreement with the Company following the expiration of its current term in June 2022. The Company also incurred transaction and integration costs of $18.3 million, primarily associated with the acquisition of Cardiva Medical, during the fourth quarter of fiscal 2021.
3
FISCAL 2022 GUIDANCE
The Company issued its GAAP total revenue growth guidance of 13 – 18% and organic revenue growth guidance as follows:
Organic1 | |||||
| Total revenue | 8 - 12% | ||||
| Plasma revenue | 15 - 25% | ||||
| Hospital Revenue | 15 - 20% | ||||
| Blood Center revenue | (6 - 8%) | ||||
1Excludes the impact of currency fluctuation, strategic exits of product lines, acquisitions and divestitures and the impact of the 53rd week in fiscal 2021. Reconciliations of reported to organic revenue are provided in the schedules accompanying this release and in the analytical tables referenced below. | |||||
Total company GAAP revenue guidance includes $65 - $75 million revenue related to our Cardiva Medical Vascular Closure devices. Hospital organic revenue guidance includes a Hemostasis Management organic revenue growth in the mid-twenties.
Additionally, the Company issued its adjusted operating margin, adjusted earnings per diluted share and free cash flow before restructuring and turnaround guidance as follows:
| Adjusted operating margin | 19 - 20% | ||||
| Adjusted earnings per diluted share | $2.60 - $3.00 | ||||
| Free cash flow, before restructuring & turnaround | $135M - $155M | ||||
WEBCAST CONFERENCE CALL AND RESULTS ANALYSIS
The Company will host a conference call with investors and analysts to discuss fourth quarter and fiscal 2021 results on Thursday, May 13, 2021 at 8:00am EDT. Interested parties may participate by telephone by dialing (877) 848-8880 from within the U.S. or Canada or (716) 335-9512 from international locations, using the access code 8694785. Alternatively, a live webcast of the call can be accessed on Haemonetics’ investor relations website at the following direct link: https://edge.media-server.com/mmc/p/xqyzme3t
The Company is posting this press release to its Investor Relations website, in addition to results analyses that will be referenced on the webcast. These analyses can be accessed at the following direct link: https://haemonetics.gcs-web.com/static-files/aedee021-4974-49c9-97bb-aaa441c4fc95
ABOUT HAEMONETICS
Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative hematology products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com.
4
FORWARD-LOOKING STATEMENTS
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements in this press release may include, without limitation, statements regarding (i) plans and objectives of management for operations of the Company, including plans or objectives related to the development and commercialization of, and regulatory approvals related to, the Company’s products, plans or objectives related to the Operational Excellence Program; (ii) estimates or projections of financial results, financial condition, capital expenditures, capital structure or other financial items, (iii) the impact of the COVID-19 pandemic on the Company’s operations, availability and demand for its products, and future financial performance, and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences.
Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the impact of the COVID-19 pandemic, including the scope and duration of the outbreak; government actions and restrictive measures implemented in response; availability and demand for the Company’s products; the Company’s ability to implement as planned and realize estimated cost savings from the Operational Excellence Program; the Company’s ability to execute business continuity plans; risks arising from the Company’s acquisition of Cardiva Medical, including any failure to realize the anticipated benefits of the transaction; the possibility that CSL Plasma, Ltd. may determine to renew it U.S. supply agreement with the Company for additional periods; technological advances in the medical field and standards for transfusion medicine and the Company’s ability to successfully offer products that incorporate such advances and standards; product quality; market acceptance; regulatory uncertainties, including in the receipt or timing of regulatory approvals; the effect of economic and political conditions; the impact of competitive products and pricing; blood product reimbursement policies and practices; and the effect of industry consolidation as seen in the plasma market. These and other factors are identified and described in more detail in the Company's periodic reports and other filings with the U.S. Securities and Exchange Commission (the “SEC”). The Company does not undertake to update these forward-looking statements.
MANAGEMENT’S USE OF NON-GAAP MEASURES
This press release contains financial measures that are considered “non-GAAP” financial measures under applicable SEC rules and regulations. Management uses non-GAAP measures to monitor the financial performance of the business, make informed business decisions, establish budgets and forecast future results. Performance targets for management are also based on certain non-GAAP financial measures. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, the Company’s reported financial results prepared in accordance with U.S. GAAP. In this release, supplemental non-GAAP measures
5
have been provided to assist investors in evaluating the performance of the Company’s core operations and provide a baseline for analyzing trends in the Company’s underlying businesses. We strongly encourage investors to review the Company’s financial statements and publicly-filed reports in their entirety and not rely on any single financial measure.
When used in this release, organic revenue growth excludes the impact of currency fluctuation, strategic exits of product lines, acquisitions and divestitures and the impact of the 53rd week in fiscal 2021. Adjusted gross profit, adjusted operating expenses, adjusted operating income, adjusted net income and adjusted earnings per diluted share exclude restructuring and turnaround costs, deal amortization expenses, asset impairments, accelerated device depreciation and related costs, costs related to compliance with the European Union Medical Device Regulation, transaction and integration costs, gains and losses on dispositions and certain tax settlements and unusual or infrequent and material litigation-related charges. Adjusted net income and adjusted earnings per diluted share also exclude the tax impact of these items. Free cash flow before restructuring and turnaround is defined as cash provided by operating activities less capital expenditures, net of the proceeds from the sale of property, plant and equipment. Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures to similarly titled measures used by other companies.
A reconciliation of non-GAAP historical financial measures to their most comparable GAAP measure are included at the end of the financial sections of this press release as well as on the Company’s website at www.haemonetics.com. The Company does not provide a quantitative reconciliation of its forward-looking organic revenue growth guidance by business unit to the comparable GAAP measure because forecasting the impact of foreign currency fluctuations by business unit is inherently uncertain and difficult to predict and is unavailable without unreasonable efforts. Additionally, the Company does not attempt to provide reconciliations of forward-looking adjusted operating margin guidance, adjusted earnings per diluted share guidance or free cash flow before restructuring and turnaround guidance to the comparable GAAP measures because the combined impact and timing of recognition of certain potential charges or gains, such as restructuring costs and impairment charges, is inherently uncertain and difficult to predict and is unavailable without unreasonable efforts. In addition, the Company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. Such items could have a substantial impact on GAAP measures of the Company’s financial performance.
6
| Haemonetics Corporation Financial Summary | ||||||||||||||||||||
| Condensed Consolidated Statements of (Loss) Income for the Fourth Quarter of FY21 and FY20 | ||||||||||||||||||||
| (Data in thousands, except per share data) | ||||||||||||||||||||
| 4/3/2021 | 3/28/2020 | % Inc/(Dec) | ||||||||||||||||||
| vs Prior Year | ||||||||||||||||||||
| (unaudited) | ||||||||||||||||||||
| Net revenues | $ | 225,029 | $ | 238,492 | (5.6)% | |||||||||||||||
| Gross profit | 81,807 | 113,557 | (28.0)% | |||||||||||||||||
| R&D | 10,843 | 8,974 | 20.8% | |||||||||||||||||
| S,G&A | 83,712 | 70,511 | 18.7% | |||||||||||||||||
| Amortization of intangible assets | 8,626 | 8,065 | 7.0% | |||||||||||||||||
| Gains on divestitures and sale of assets | (199) | — | n/m | |||||||||||||||||
| Operating expenses | 102,982 | 87,550 | 17.6% | |||||||||||||||||
| Operating (loss) income | (21,175) | 26,007 | n/m | |||||||||||||||||
| Interest and other expense, net | (6,222) | (4,047) | 53.7% | |||||||||||||||||
| (Loss) income before taxes | (27,397) | 21,960 | n/m | |||||||||||||||||
| Tax (benefit) expense | (16,356) | 4,336 | n/m | |||||||||||||||||
| Net (loss) income | $ | (11,041) | $ | 17,624 | n/m | |||||||||||||||
| Net (loss) income per common share assuming dilution | $ | (0.22) | $ | 0.34 | n/m | |||||||||||||||
| Weighted average number of shares: | ||||||||||||||||||||
| Basic | 50,848 | 50,338 | ||||||||||||||||||
| Diluted | 50,848 | 51,275 | ||||||||||||||||||
| Profit Margins: | Inc/(Dec) vs prior year profit margin % | |||||||||||||||||||
| Gross profit | 36.4 | % | 47.6 | % | (11.2)% | |||||||||||||||
| R&D | 4.8 | % | 3.8 | % | 1.0% | |||||||||||||||
| S,G&A | 37.2 | % | 29.6 | % | 7.6% | |||||||||||||||
| Operating (loss) income | (9.4) | % | 10.9 | % | (20.3)% | |||||||||||||||
| (Loss) income before taxes | (12.2) | % | 9.2 | % | (21.4)% | |||||||||||||||
| Net (loss) income | (4.9) | % | 7.4 | % | (12.3)% | |||||||||||||||
7
| Haemonetics Corporation Financial Summary | ||||||||||||||||||||
| Condensed Consolidated Statements of Income for Year-to-Date FY21 and FY20 | ||||||||||||||||||||
| (Data in thousands, except per share data) | ||||||||||||||||||||
| 4/3/2021 | 3/28/2020 | % Inc/(Dec) | ||||||||||||||||||
| vs Prior Year | ||||||||||||||||||||
| (unaudited) | ||||||||||||||||||||
| Net revenues | $ | 870,463 | $ | 988,479 | (11.9)% | |||||||||||||||
| Gross profit | 397,838 | 484,513 | (17.9)% | |||||||||||||||||
| R&D | 32,857 | 30,883 | 6.4% | |||||||||||||||||
| S,G&A | 274,188 | 282,017 | (2.8)% | |||||||||||||||||
| Amortization of intangible assets | 32,830 | 25,746 | 27.5% | |||||||||||||||||
| Impairment of assets | 1,028 | 50,599 | (98.0)% | |||||||||||||||||
| Gains on divestitures and sale of assets | (32,812) | (8,083) | n/m | |||||||||||||||||
| Operating expenses | 308,091 | 381,162 | (19.2)% | |||||||||||||||||
| Operating income | 89,747 | 103,351 | (13.2)% | |||||||||||||||||
| Interest and other expense, net | (16,834) | (16,199) | 3.9% | |||||||||||||||||
| Income before taxes | 72,913 | 87,152 | (16.3)% | |||||||||||||||||
| Tax (benefit) expense | (6,556) | 10,626 | n/m | |||||||||||||||||
| Net income | $ | 79,469 | $ | 76,526 | 3.8% | |||||||||||||||
| Net income per common share assuming dilution | $ | 1.55 | $ | 1.48 | 4.7% | |||||||||||||||
| Weighted average number of shares: | ||||||||||||||||||||
| Basic | 50,688 | 50,692 | ||||||||||||||||||
| Diluted | 51,292 | 51,815 | ||||||||||||||||||
| Profit Margins: | Inc/(Dec) vs prior year profit margin % | |||||||||||||||||||
| Gross profit | 45.7 | % | 49.0 | % | (3.3)% | |||||||||||||||
| R&D | 3.8 | % | 3.1 | % | 0.7% | |||||||||||||||
| S,G&A | 31.5 | % | 28.5 | % | 3.0% | |||||||||||||||
| Operating income | 10.3 | % | 10.5 | % | (0.2)% | |||||||||||||||
| Income before taxes | 8.4 | % | 8.8 | % | (0.4)% | |||||||||||||||
| Net income | 9.1 | % | 7.7 | % | 1.4% | |||||||||||||||
8
| Revenue Analysis for the Fourth Quarter of FY21 and FY20 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| (Data in thousands) | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Three Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||
| 4/3/2021 | 3/28/2020 | Reported growth | Currency impact | Acquisition and Divestitures(1) | Other Strategic Exits(2) | 53rd Week | Organic Growth | |||||||||||||||||||||||||||||||||||||||||||
| (unaudited) | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Revenues by business unit | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Plasma | $ | 83,683 | $ | 111,914 | (25.2) | % | 0.3 | % | — | % | (4.6) | % | 7.4 | % | (28.3) | % | ||||||||||||||||||||||||||||||||||
| Blood Center | 73,830 | 76,565 | (3.6) | % | 3.7 | % | (5.0) | % | — | % | 7.5 | % | (9.8) | % | ||||||||||||||||||||||||||||||||||||
Hospital (3) | 62,164 | 45,772 | 35.8 | % | 4.6 | % | 14.2 | % | — | % | 5.3 | % | 11.7 | % | ||||||||||||||||||||||||||||||||||||
| Net business unit revenues | $ | 219,677 | $ | 234,251 | (6.2) | % | 2.2 | % | 1.5 | % | (1.5) | % | 5.9 | % | (14.3) | % | ||||||||||||||||||||||||||||||||||
| Service | 5,352 | 4,241 | 26.2 | % | 6.8 | % | — | % | — | % | — | % | 19.4 | % | ||||||||||||||||||||||||||||||||||||
| Total net revenues | $ | 225,029 | $ | 238,492 | (5.6) | % | 2.2 | % | 1.5 | % | (1.5) | % | 5.9 | % | (13.7) | % | ||||||||||||||||||||||||||||||||||
(1)Reflects the divestiture impacts of (3.9%) related to the Company’s U.S. blood donor management software solutions assets and (1.0%) related to Inlog Holdings France SAS (“InLog”) in Blood Center. Also reflects the impacts of 16.2%,1.3% and (3.3%) in Hospital related to the acquisitions of Cardiva Medical Inc, and enicor GMBH and the divestiture of InLog, respectively. (2) Reflects adjustments to both fiscal 2021 and 2020 Plasma revenue due to certain strategic exits within the liquid solutions business. (3) Hospital revenue includes Hemostasis Management revenue of $28.9 million and $21.8 million for the three months ended April 3, 2021 and March 28, 2020, respectively. Hemostasis Management revenue increased 32.6% in the fourth quarter of fiscal 2021 as compared with the same period of fiscal 2020. Hemostasis Management revenue increased 19.1%, on an organic basis, in the fourth quarter of fiscal 2021 as compared with the same period of fiscal 2020. | ||||||||||||||||||||||||||||||||||||||||||||||||||
9
| Revenue Analysis for Year-to-Date FY21 and FY20 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| (Data in thousands) | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Year Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||
| 4/3/2021 | 3/28/2020 | Reported growth | Currency impact | Acquisition and Divestitures(1) | Other Strategic Exits(2) | 53rd Week | Organic Growth | |||||||||||||||||||||||||||||||||||||||||||
| (unaudited) | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Revenues by business unit | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Plasma | $ | 332,236 | $ | 458,681 | (27.6) | % | — | % | — | % | (1.8) | % | 0.6 | % | (26.4) | % | ||||||||||||||||||||||||||||||||||
| Blood Center | 307,452 | 317,761 | (3.2) | % | 2.4 | % | (2.7) | % | — | % | 1.4 | % | (4.3) | % | ||||||||||||||||||||||||||||||||||||
Hospital (3) | 210,632 | 193,437 | 8.9 | % | 0.7 | % | 3.3 | % | — | % | 1.3 | % | 3.6 | % | ||||||||||||||||||||||||||||||||||||
| Net business unit revenues | $ | 850,320 | $ | 969,879 | (12.3) | % | 1.0 | % | (0.2) | % | (0.8) | % | 0.6 | % | (12.9) | % | ||||||||||||||||||||||||||||||||||
| Service | 20,143 | 18,600 | 8.3 | % | 3.6 | % | — | % | — | % | — | % | 4.7 | % | ||||||||||||||||||||||||||||||||||||
| Total net revenues | $ | 870,463 | $ | 988,479 | (11.9) | % | 1.0 | % | (0.2) | % | (0.8) | % | 0.6 | % | (12.5) | % | ||||||||||||||||||||||||||||||||||
(1)Reflects the divestiture impacts of (2.5%) related to the Company’s U.S. blood donor management software solutions assets and (0.2%) related to Inlog Holdings France SAS (“InLog”) in Blood Center. Also reflects the impacts of 3.9%, 1.0%, and (1.6%) in Hospital related to the acquisitions of Cardiva Medical, Inc., enicor GMBH and the divestiture of InLog, respectively. (2) Reflects adjustments to both fiscal 2021 and 2020 Plasma revenue due to certain strategic exits within the liquid solutions business. (3) Hospital revenue includes Hemostasis Management revenue of $107.4 million and $95.7 million for fiscal 2021 and 2020, respectively. Hemostasis Management revenue increased 12.2% in fiscal 2021 as compared with fiscal 2020. Hemostasis Management revenue increased 9.0%, on an organic basis, in fiscal 2021 as compared fiscal 2020. | ||||||||||||||||||||||||||||||||||||||||||||||||||
10
| Condensed Consolidated Balance Sheets | |||||||||||||||||
| (Data in thousands) | |||||||||||||||||
| As of | |||||||||||||||||
| 4/3/2021 | 3/28/2020 | ||||||||||||||||
| (unaudited) | |||||||||||||||||
| Assets | |||||||||||||||||
| Cash and cash equivalents | $ | 192,305 | $ | 137,311 | |||||||||||||
| Accounts receivable, net | 127,555 | 165,207 | |||||||||||||||
| Inventories, net | 322,614 | 270,276 | |||||||||||||||
| Other current assets | 51,072 | 30,845 | |||||||||||||||
| Total current assets | 693,546 | 603,639 | |||||||||||||||
| Property, plant & equipment, net | 217,559 | 253,399 | |||||||||||||||
| Intangible assets, net | 365,483 | 133,106 | |||||||||||||||
| Goodwill | 466,444 | 210,652 | |||||||||||||||
| Other assets | 76,891 | 66,314 | |||||||||||||||
| Total assets | $ | 1,819,923 | $ | 1,267,110 | |||||||||||||
| Liabilities & Stockholders' Equity | |||||||||||||||||
| Short-term debt & current maturities | $ | 17,016 | $ | 76,980 | |||||||||||||
| Other current liabilities | 236,479 | 197,842 | |||||||||||||||
| Total current liabilities | 253,495 | 274,822 | |||||||||||||||
| Long-term debt | 690,592 | 305,513 | |||||||||||||||
| Other long-term liabilities | 144,166 | 99,666 | |||||||||||||||
| Stockholders' equity | 731,670 | 587,109 | |||||||||||||||
| Total liabilities & stockholders' equity | $ | 1,819,923 | $ | 1,267,110 | |||||||||||||
11
| Condensed Consolidated Statements of Cash Flows | |||||||||||
| (Data in thousands) | |||||||||||
| Year Ended | |||||||||||
| 4/3/2021 | 3/28/2020 | ||||||||||
| (unaudited) | |||||||||||
| Cash Flows from Operating Activities: | |||||||||||
| Net income | $ | 79,469 | $ | 76,526 | |||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||||||||
| Depreciation and amortization | 84,287 | 110,289 | |||||||||
| Gain on sale of assets | (32,812) | (8,083) | |||||||||
| Share-based compensation expense | 25,516 | 20,454 | |||||||||
| Impairment of assets | 21,969 | 50,599 | |||||||||
| Provision (benefit) for losses on inventory | 7,860 | (2,904) | |||||||||
| Change in other non-cash operating activities | (17,802) | (4,102) | |||||||||
| Change in accounts receivable, net | 44,121 | 18,863 | |||||||||
| Change in inventories | (38,909) | (84,721) | |||||||||
| Change in other working capital | (64,894) | (18,704) | |||||||||
| Net cash provided by operating activities | 108,805 | 158,217 | |||||||||
| Cash Flows from Investing Activities: | |||||||||||
| Capital expenditures | (37,040) | (48,758) | |||||||||
| Acquisitions | (434,804) | (35,000) | |||||||||
| Proceeds from sale of property, plant and equipment | 1,815 | 16,774 | |||||||||
| Proceeds from divestitures | 44,587 | 9,808 | |||||||||
| Net cash used in investing activities | (425,442) | (57,176) | |||||||||
| Cash Flows from Financing Activities: | |||||||||||
| Proceeds from issuance of convertible notes | 500,000 | — | |||||||||
| Purchase of capped call related to convertible notes | (47,400) | — | |||||||||
| Transaction costs paid in connection with convertible notes issuance | (13,457) | — | |||||||||
| Borrowings, net of repayments | (81,875) | 31,875 | |||||||||
| Proceeds from employee stock programs | 10,230 | 12,016 | |||||||||
| Share repurchases | — | (175,000) | |||||||||
| Other | (46) | (99) | |||||||||
| Net cash provided by (used) in financing activities | 367,452 | (131,208) | |||||||||
| Effect of exchange rates on cash and cash equivalents | 4,179 | (1,873) | |||||||||
| Net Change in Cash and Cash Equivalents | 54,994 | (32,040) | |||||||||
| Cash and Cash Equivalents at Beginning of the Period | 137,311 | 169,351 | |||||||||
| Cash and Cash Equivalents at End of Period | $ | 192,305 | $ | 137,311 | |||||||
| Free Cash Flow Reconciliation: | |||||||||||
| Cash provided by operating activities | $ | 108,805 | $ | 158,217 | |||||||
| Capital expenditures, net of proceeds from sale of property, plant and equipment | (35,225) | (31,984) | |||||||||
| Free cash flow after restructuring and turnaround costs | $ | 73,580 | $ | 126,233 | |||||||
| Restructuring and turnaround costs | 32,639 | 20,614 | |||||||||
| Tax benefit on restructuring and turnaround costs | (7,017) | (7,431) | |||||||||
Free cash flow before restructuring and turnaround costs(1) | $ | 99,202 | $ | 139,416 | |||||||
(1) Free cash flow before restructuring & turnaround does not include net cash proceeds of $15.0 million from the sale of the Company’s Braintree corporate headquarters during the fiscal 2020. | |||||||||||
12
| Reconciliation of Adjusted Measures for the Fourth Quarter of FY21 and FY20 | |||||||||||
| (Data in thousands except per share data) | |||||||||||
| Three Months Ended | |||||||||||
| 4/3/2021 | 3/28/2020 | ||||||||||
| (unaudited) | |||||||||||
| GAAP gross profit | $ | 81,807 | $ | 113,557 | |||||||
| Impairment of assets, PCS2 accelerated depreciation and other related charges | 21,276 | 4,813 | |||||||||
| Restructuring and turnaround costs | 2,869 | 1,583 | |||||||||
| Transaction and integration costs | 6,471 | — | |||||||||
| Adjusted gross profit | $ | 112,423 | $ | 119,953 | |||||||
| GAAP operating expenses | $ | 102,982 | $ | 87,550 | |||||||
| Deal amortization | (8,626) | (8,065) | |||||||||
| Transaction and integration costs | (8,887) | (568) | |||||||||
| Restructuring and turnaround costs | (1,209) | (4,713) | |||||||||
| European Medical Device Regulation costs | (1,434) | (501) | |||||||||
| Impairment of assets, PCS2 accelerated depreciation and other related charges | (192) | (1,009) | |||||||||
Litigation-related charges(1) | (897) | — | |||||||||
Gains on divestitures and sale of assets(2) | 199 | — | |||||||||
| Adjusted operating expenses | $ | 81,936 | $ | 72,694 | |||||||
| GAAP operating (loss) income | $ | (21,175) | $ | 26,007 | |||||||
| Deal amortization | 8,626 | 8,065 | |||||||||
| Impairment of assets, PCS2 accelerated depreciation and other related charges | 21,468 | 5,822 | |||||||||
| Transaction and integration costs | 15,358 | 568 | |||||||||
| Restructuring and turnaround costs | 4,078 | 6,296 | |||||||||
| European Medical Device Regulation costs | 1,434 | 501 | |||||||||
Litigation-related charges(1) | 897 | — | |||||||||
Gains on divestitures and sale of assets(2) | (199) | — | |||||||||
| Adjusted operating income | $ | 30,487 | $ | 47,259 | |||||||
| GAAP net (loss) income | $ | (11,041) | $ | 17,624 | |||||||
| Deal amortization | 8,626 | 8,065 | |||||||||
| Impairment of assets, PCS2 accelerated depreciation and other related charges | 21,468 | 5,822 | |||||||||
| Transaction and integration costs | 18,328 | 568 | |||||||||
| Restructuring and turnaround costs | 4,078 | 6,296 | |||||||||
| European Medical Device Regulation costs | 1,434 | 501 | |||||||||
| Tax settlement | 1,083 | 795 | |||||||||
Litigation-related charges(1) | 897 | — | |||||||||
Gains on divestitures and sale of assets(2) | (199) | — | |||||||||
| Tax impact associated with adjustments | (20,782) | (4,258) | |||||||||
| Adjusted net income | $ | 23,892 | $ | 35,413 | |||||||
GAAP net (loss) income per common share(3) | $ | (0.22) | $ | 0.34 | |||||||
| Adjusted items after tax per common share assuming dilution | 0.68 | 0.35 | |||||||||
Adjusted net income per common share assuming dilution(4) | $ | 0.46 | $ | 0.69 | |||||||
(1) Reflects costs incurred related to a litigation-related matter in fiscal 2021 and the impact of the resolution of customer damages assessments associated with product recalls in fiscal 2020. (2) Reflects gains on divestitures in fiscal 2021 and the gain on the sale of the Company's Braintree corporate headquarters in fiscal 2020. (3) GAAP net loss per common share is calculated using weighted average basic shares outstanding and excludes the impact of outstanding stock awards from the diluted loss per share calculation as their inclusion would have an anti-dilutive effect. (4) Adjusted net income per common share is calculated using weighted average diluted shares outstanding of 51,463 which includes the impact of outstanding stock awards. | |||||||||||
13
| Reconciliation of Adjusted Measures for Year-to-Date FY21 and FY20 | |||||||||||
| (Data in thousands except per share data) | |||||||||||
| Year Ended | |||||||||||
| 4/3/2021 | 3/28/2020 | ||||||||||
| (unaudited) | |||||||||||
| GAAP gross profit | $ | 397,838 | $ | 484,513 | |||||||
Impairment of assets, PCS2 accelerated depreciation and other related charges(1) | 23,460 | 23,011 | |||||||||
| Restructuring and turnaround costs | 9,708 | 3,309 | |||||||||
| Transaction and integration costs | 6,561 | — | |||||||||
| Adjusted gross profit | $ | 437,567 | $ | 510,833 | |||||||
| GAAP operating expenses | $ | 308,091 | $ | 381,162 | |||||||
| Deal amortization | (32,830) | (25,746) | |||||||||
| Transaction and integration costs | (11,860) | (568) | |||||||||
| Restructuring and turnaround costs | (5,953) | (16,569) | |||||||||
| European Medical Device Regulation costs | (4,130) | (1,506) | |||||||||
| Impairment of assets, PCS2 accelerated depreciation and other related charges | (2,236) | (52,739) | |||||||||
Litigation-related charges(2) | (897) | 701 | |||||||||
Gains on divestitures and sale of assets(3) | 32,812 | 8,083 | |||||||||
| Adjusted operating expenses | $ | 282,997 | $ | 292,818 | |||||||
| GAAP operating income | $ | 89,747 | $ | 103,351 | |||||||
| Deal amortization | 32,830 | 25,746 | |||||||||
Impairment of assets, PCS2 accelerated depreciation and other related charges(1) | 25,696 | 75,750 | |||||||||
| Transaction and integration costs | 18,421 | 568 | |||||||||
| Restructuring and turnaround costs | 15,661 | 19,878 | |||||||||
| European Medical Device Regulation costs | 4,130 | 1,506 | |||||||||
Litigation-related charges(2) | 897 | (701) | |||||||||
Gains on divestitures and sale of assets(3) | (32,812) | (8,083) | |||||||||
| Adjusted operating income | $ | 154,570 | $ | 218,015 | |||||||
| GAAP net income | $ | 79,469 | $ | 76,526 | |||||||
| Deal amortization | 32,830 | 25,746 | |||||||||
Impairment of assets, PCS2 accelerated depreciation and other related charges(1) | 25,696 | 75,750 | |||||||||
| Transaction and integration costs | 21,391 | 568 | |||||||||
| Restructuring and turnaround costs | 15,661 | 19,878 | |||||||||
| European Medical Device Regulation costs | 4,130 | 1,506 | |||||||||
| Tax settlement | 1,083 | 795 | |||||||||
Litigation-related charges(2) | 897 | (701) | |||||||||
Gains on divestitures and sale of assets(3) | (32,812) | (8,083) | |||||||||
| Tax impact associated with adjustments | (27,646) | (20,689) | |||||||||
| Adjusted net income | $ | 120,699 | $ | 171,296 | |||||||
| GAAP net income per common share | $ | 1.55 | $ | 1.48 | |||||||
| Adjusted items after tax per common share assuming dilution | 0.80 | 1.83 | |||||||||
| Adjusted net income per common share assuming dilution | $ | 2.35 | $ | 3.31 | |||||||
(1) Includes a $1.9 million adjustment to fiscal 2020 Plasma revenue due to an accelerated charge incurred as a result of the divestiture of the Union, South Carolina liquid solutions operations. (2) Reflects costs incurred related to a litigation-related matter in fiscal 2021 and the impact of the resolution of customer damages assessments associated with product recalls in fiscal 2020. (3) Reflects gains on divestitures in fiscal 2021 and the gain on the sale of the Company's Braintree corporate headquarters in fiscal 2020. | |||||||||||
14
| Projected Fiscal 2022 GAAP and Organic Revenue Growth Rates | |||||
| FY 2022 | |||||
| GAAP Revenue Growth | 13 - 18% | ||||
| Currency impact | (1-2%) | ||||
Acquisitions and divestitures(1) | (6%) | ||||
Other strategic exits(2) | 1% | ||||
53rd week(3) | 1% | ||||
| Organic Revenue Growth | 8 - 12% | ||||
(1) Reflects adjustment to fiscal 2021 revenue as a result of the divestiture of the Company’s U.S. blood donor management software solutions assets and Inlog Holdings France SAS, as well as an adjustment to fiscal 2022 revenue related to the acquisition of Cardiva Medical, Inc. (2) Reflects adjustments to Plasma revenue due to certain strategic exits within the liquid solutions business. (3) Reflects adjustment to fiscal 2021 revenue for the impact of the 53rd week. | |||||
15